These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
822 related articles for article (PubMed ID: 18199863)
1. Etanercept treatment for children and adolescents with plaque psoriasis. Paller AS; Siegfried EC; Langley RG; Gottlieb AB; Pariser D; Landells I; Hebert AA; Eichenfield LF; Patel V; Creamer K; Jahreis A; N Engl J Med; 2008 Jan; 358(3):241-51. PubMed ID: 18199863 [TBL] [Abstract][Full Text] [Related]
2. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis. Landells I; Paller AS; Pariser D; Kricorian G; Foehl J; Molta C; Freundlich B Eur J Dermatol; 2010; 20(3):323-8. PubMed ID: 20185386 [TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937 [TBL] [Abstract][Full Text] [Related]
5. Intermittent etanercept therapy in pediatric patients with psoriasis. Siegfried EC; Eichenfield LF; Paller AS; Pariser D; Creamer K; Kricorian G J Am Acad Dermatol; 2010 Nov; 63(5):769-74. PubMed ID: 20833444 [TBL] [Abstract][Full Text] [Related]
6. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Papp KA; Tyring S; Lahfa M; Prinz J; Griffiths CE; Nakanishi AM; Zitnik R; van de Kerkhof PC; Melvin L; Br J Dermatol; 2005 Jun; 152(6):1304-12. PubMed ID: 15948997 [TBL] [Abstract][Full Text] [Related]
7. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis. Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256 [TBL] [Abstract][Full Text] [Related]
8. A randomized trial of etanercept as monotherapy for psoriasis. Gottlieb AB; Matheson RT; Lowe N; Krueger GG; Kang S; Goffe BS; Gaspari AA; Ling M; Weinstein GD; Nayak A; Gordon KB; Zitnik R Arch Dermatol; 2003 Dec; 139(12):1627-32; discussion 1632. PubMed ID: 14676082 [TBL] [Abstract][Full Text] [Related]
9. Long-term etanercept in pediatric patients with plaque psoriasis. Paller AS; Siegfried EC; Eichenfield LF; Pariser D; Langley RG; Creamer K; Kricorian G J Am Acad Dermatol; 2010 Nov; 63(5):762-8. PubMed ID: 20605256 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Mazzotta A; Esposito M; Costanzo A; Chimenti S Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444 [TBL] [Abstract][Full Text] [Related]
11. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. Moore A; Gordon KB; Kang S; Gottlieb A; Freundlich B; Xia HA; Stevens SR J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190 [TBL] [Abstract][Full Text] [Related]
12. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A; N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701 [TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Elewski B; Leonardi C; Gottlieb AB; Strober BE; Simiens MA; Dunn M; Jahreis A Br J Dermatol; 2007 Jan; 156(1):138-42. PubMed ID: 17199580 [TBL] [Abstract][Full Text] [Related]
14. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R; Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis. Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320 [TBL] [Abstract][Full Text] [Related]
16. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Strober B; Teller C; Yamauchi P; Miller JL; Hooper M; Yang YC; Dann F Br J Dermatol; 2008 Aug; 159(2):322-30. PubMed ID: 18503600 [TBL] [Abstract][Full Text] [Related]
17. Two years of experience with etanercept in recalcitrant psoriasis. Ahmad K; Rogers S Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393 [TBL] [Abstract][Full Text] [Related]
18. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657 [TBL] [Abstract][Full Text] [Related]
19. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Gisondi P; Del Giglio M; Cotena C; Girolomoni G Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408 [TBL] [Abstract][Full Text] [Related]